Holen Sie sich die Stockscreener-App
57.58
7.75%
-4.84
Handel nachbörslich:
57.58
Merus N V Aktie (MRUS) Neueste Nachrichten
Merus Raises $300m After ASCO Success - insights.citeline.com
Sector Update: Health Care Stocks Mixed Premarket Wednesday - marketscreener.com
Merus dips 7%, prices $300M stock at $57 per share - MSN
Merus N.V. announces proposed public offering of common shares - MSN
MRUS: Joint Managers Lead Successful Offering | MRUS Stock News - GuruFocus
Merus Prices $300 Million Stock Offering - marketscreener.com
Merus N.V. (MRUS) Launches $300M Public Offering - GuruFocus
Merus Prices 5.26 Mln Shares At $57/Shr In Public Offering; To Raise Around $300 Mln - Nasdaq
Merus N.V. Announces Pricing of Public Offering of Common Shares - The Manila Times
Merus (MRUS) Initiates Public Offering to Fund Development | MRU - GuruFocus
Merus (MRUS) Initiates Public Offering to Fund Development | MRUS Stock News - GuruFocus
Merus Plans Public Share Offering - marketscreener.com
Drugmaker Merus slips after share offering launch - TradingView
Merus N.V. announces public offering of common shares - Investing.com
Merus N.V. Announces Proposed Public Offering of Common Shares | MRUS Stock News - GuruFocus
Merus N.V. Announces Proposed Public Offering of Common Shares - GlobeNewswire
Merus N.V. Announces Proposed Public Offering of Common Shares - Benzinga
How to Take Advantage of moves in (MRUS) - news.stocktradersdaily.com
e.l.f Beauty, Box And Joby Aviation Are Among Top 11 Mid-Cap Gainers Last Week (May 26-May 30): Are Others In Your Portfolio? - Benzinga
Merus, N.V. Provides Updates on Clinical Development - marketscreener.com
Merus NV Stock Skyrockets 8%: Bull Run Intact or Peak Approaching? - Daily Chhattisgarh News
Merus Announces Promising Phase 2 Trial Results - TipRanks
Merus to Present at Upcoming Investor Conferences - GlobeNewswire
Merus Showcases Next-Gen Cancer Antibody Platform at Two Premier Healthcare Conferences - Stock Titan
Merus stock holds $85 target, Buy rating at H.C. Wainwright - Investing.com
Merus stock holds $85 target, Buy rating at H.C. Wainwright By Investing.com - Investing.com India
Merus (MRUS) Stock: Analysts Rally Behind Biotech After Cancer Treatment Breakthrough - CoinCentral
Merus gains after mid-stage trial data for lead asset in head and neck cancer - MSN
Merus (NASDAQ:MRUS) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Merus (NASDAQ:MRUS) Given a $110.00 Price Target by BMO Capital Markets Analysts - Defense World
Lazard Asset Management LLC Takes Position in Merus (NASDAQ:MRUS) - Defense World
Merus (NASDAQ:MRUS) Price Target Raised to $110.00 - Defense World
BofA Maintains Buy Rating on Merus (MRUS), Lifts PT - Yahoo Finance
Merus N.V.’s SWOT analysis: promising cancer drug pipeline boosts stock outlook - Investing.com Australia
Merus (MRUS) Price Target Raised at BMO After Positive Phase 2 Data - MSN
Merus shares rise as Needham lifts price target to $88 By Investing.com - Investing.com South Africa
Merus stock price target raised to $110 at BMO Capital - Investing.com Australia
Merus stock target holds at $88, Truist affirms Buy rating By Investing.com - Investing.com South Africa
Northern Trust Corp Has $3.21 Million Stake in Merus (NASDAQ:MRUS) - Defense World
Merus N.V.’s SWOT analysis: promising cancer drug pipeline boosts stock outlook By Investing.com - Investing.com South Africa
Merus stock target holds at $88, Truist affirms Buy rating - Investing.com Australia
Merus shares rise as Needham lifts price target to $88 - Investing.com Australia
Big Gains For Imunon, Merus, And Douglas Elliman - Finimize
Merus stock price target raised to $110 at BMO Capital By Investing.com - Investing.com Nigeria
Vorläufige Ergebnisse von Merus zu Petosemtamab mit - GlobeNewswire
Merus (NASDAQ:MRUS) Shares Gap Up After Analyst Upgrade - Defense World
Learn to Evaluate (MRUS) using the Charts - news.stocktradersdaily.com
Merus updates on Petosemtamab+Pembrolizumab data in HNSCC - Yahoo Finance
Merus’ ASCO data bolster case for first-in-class bispecific - BioCentury
Merus combo trounces Keytruda in head-and-neck phase II - BioWorld MedTech
Sector Update: Health Care Stocks Decline Late Afternoon - marketscreener.com
0.00%
0.54%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):